Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zyprexa IM Manufacturing Issues To Be Discussed By FDA, Lilly March 15

Executive Summary

Lilly hopes to be ready for a re-inspection of its intramuscular Zyprexa production facility in mid-May, ahead of the late June user fee deadline for a decision on the new formulation of the antipsychotic.

You may also be interested in...



FDA Approves Zyprexa IM; Milestone In Lilly GMP Turnaround

Lilly's Zyprexa IM has cleared FDA three years after a pre-approval inspection for the intramuscular antipsychotic triggered a period of Good Manufacturing Practices compliance issues for the company

FDA Approves Zyprexa IM; Milestone In Lilly GMP Turnaround

Lilly's Zyprexa IM has cleared FDA three years after a pre-approval inspection for the intramuscular antipsychotic triggered a period of Good Manufacturing Practices compliance issues for the company

Lilly Expects Full GMP Inspection After Upgrades To “Building 105”

Lilly is planning to shut down its "Building 105" manufacturing facility in 2004 to make GMP upgrades, CEO Sidney Taurel said during a Dec. 3 analyst dinner in New York

Related Content

UsernamePublicRestriction

Register

PS037493

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel